HOME >> BIOLOGY >> NEWS
Phase II trials of second-generation antisense cancer drug planned following successful early study

Geneva, Switzerland: Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.

In the Phase I study the drug OGX-011* inhibited the production of clusterin, a protein that protects cell survival and is widely distributed in body tissue. Clusterin is implicated in a range of activities, including apoptosis (programmed cell death). When it is over-produced, as it is many major cancers, clusterin can stop cancer cells from dying and counters the effectiveness of chemotherapy, hormone treatment and radiotherapy.

Dr. Kim Chi, assistant professor of medicine at the University of British Columbia and medical oncologist at the BC Cancer Agency in Canada, told the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva today (Wednesday 29 September) that the Phase I trial was unique in that the clinical research team was able to demonstrate that the target clusterin was inhibited by OGX-011 in patients' cancers in a dose dependent way.

"This means that the drug is doing what it is supposed to be doing something that we can't always say about targeted therapeutics and we were able to identify a biologically active dose," he said.

Antisense drugs work by inhibiting the production of a protein from a specifically targeted gene. As a second-generation antisense drug, OGX-011 is an advance on earlier ones in that the molecules have a longer tissue half life and are potentially more potent. Pre-clinical studies had shown that blocking the production of clusterin with OGX-011 impairs a cancer cell's survival mechanism and enhances the effectiveness of standard chemotherapy, radiation and hormone therapy.

Twenty-five patients with localised prostate cancer that was to be removed by surgery were given escalati
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
29-Sep-2004


Page: 1 2

Related biology news :

1. OneWorld Health completes enrollment, treatment in Phase III India trial
2. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
3. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
4. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
5. KEPPRA international Phase IV SKATE study results show favourable efficacy
6. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
7. Phase III, 48-Wk NEAT study results comparing GW433908 to Nelfinavir presented today
8. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
9. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
10. Phase transition in bilayers could affect their performance
11. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... ... June 13, 2019 , ... KICVentures announced ... & The Spine, Orthopedic and Pain Management-Driven ASC Conference in Chicago on Thursday, June ... 323 E. Wacker Dr. Chicago, IL in the 3rd floor Ticino Hospitality room in ...
(Date:6/6/2019)... ... June 05, 2019 , ... Pelican BioThermal , ... station and service center in Mexico City, Mexico. Mexico is the second largest ... more than $1.75 billion in pharmaceutical exports since 2015. The Mexico City network ...
(Date:6/4/2019)... ... June 04, 2019 , ... Most ... features of seizure risk signals, usually based on variations of amplitude, frequency or ... only acceptable diagnostic methodology due to the complexity and variability of the signal, ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... ... ... For many years, the primary forms of cancer treatment have been chemotherapy, radiation ... have led to the advent of Chimeric Antigen Receptor T (CAR T) cell therapy, ... “CARs”. The CAR enables the final product to produce chemicals in the hopes that ...
(Date:5/31/2019)... ... May 30, 2019 , ... World ... Integrity on July 08-09, 2019 in Boston, MA. This peer recommended interactive workshop ... organizations. , The training will kick off with a compendial treatment of Data ...
(Date:5/31/2019)... ... May 30, 2019 , ... ... demonstrate an efficient delivery system for the sustained release of human placental stem ... gel system was able to deliver CM into the injured kidney, where it ...
(Date:5/21/2019)... , ... May 21, 2019 , ... ... Berlin (VLB) today officially opened the inaugural Africa Brewing Conference dedicated to sharing ... industry in Africa. The event, which is supported through a partnership with “Ethiopia ...
Breaking Biology Technology:
Cached News: